Received: 13 March 2020; Published on-line: 24 June 2020

Assessing quality of life in patients with ocular disturbances who underwent surgery for non-functioning pituitary adenoma

K.S. Iegorova, O.Ie. Skobska, V.M. Zhdanova, M.O. Guk

Romodanov Neurosurgery Institute, NAMS of Ukraine;    Kyiv (Ukraine)

E-mail:  iegorova_katya@ukr.net

TO CITE THIS ARTICLE: Iegorova K.S., Skobska O.Ie., Zhdanova V.M., Guk M.O. Assessing quality of life in patients with ocular disturbances who underwent surgery for non-functioning pituitary adenoma. J.ophthalmol.(Ukraine).2020;3:37-41. http://doi.org/10.31288/oftalmolzh202033741

Background: Ocular disturbances play a major role in the clinical course of non-functioning pituitary adenoma (NFPA). Partial or complete loss of sight affects patient quality of life (QoL), leading to increased dependence and poor performance; in addition, it affects the patient’s level of social adaptation. Developing a QoL questionnaire for patients with NFPA having ocular disturbances will allow for longitudinal monitoring of a patient’s condition and assessing quality of provided care.

Purpose: To develop and implement a method for assessing quality of life in patients with ocular disturbances who underwent surgery for non-functioning pituitary adenoma.

Material and Methods: We retrospectively reviewed the results of diagnostic studies and treatment outcomes among 100 patients with NFPA having ocular disturbances who received treatment at the Transsphenoidal Neurosurgery Department, Romodanov Neurosurgery Institute, during the period from 2017 through 2018. Patients underwent clinical-and-neurological, ophthalmological, otoneurological and neuroimaging examinations. We developed ocular-disturbance score assessment method and QoL scale for patients with ocular disturbances involving a number of indices related to ophthalmological symptoms, as well as to physical, psychic and social status of specific patients.

Results: The QoL scale has two subscales, subscale A (15 questions with each question having three possible responses) and subscale B (5 questions with each question having four possible responses), with the questions answered by the patient and the doctor, respectively. With the testing completed, total scores are calculated. A total QOL score of 0–15 is considered a poor (or low) QoL; 16–30, a moderate (or good) QoL; and 31–45, a high QoL. Treatment outcome monitoring and assessment of QoL over time for patients with NFPA having ocular disturbances can be performed by comparison of total pre-treatment and post-treatment scores. Not only is the extent of injury to the optic and oculomotor nerves assessed, but also the impact of physical handicap on the patient’s activities and on his or her functional abilities.

Conclusion: Implementing of the method for assessing the quality of life in patients with ocular disturbances with the help of the scale will allow for longitudinal condition monitoring in the course of treatment for patients with NFPA, making it possible to objectify treatment outcomes.

Keywords: non-functioning pituitary adenoma, ocular disturbances, oculomotor disturbances, quality of life scale


1.Abouaf L, Vighetto A, Lebas M. Neuro-ophthalmologic exploration in non-functioning pituitary adenoma. Ann Endocrinol (Paris). 2015; 76(3):210-9. DOI:10.1007 / s11102-019-00960-0.Crossref PubMed

2.Lee IH, Miller NR, Zan E, Tavares F, Blitz A, Sung H, et al. Visual Defects in Patients With Pituitary Adenomas: The Myth of Bitemporal Hemianopsia. AJR Am J Roentgenol. 2015 Nov;205(5): W512-8.Crossref PubMed

3.Kan E, Kan EK, Atmaca A, Atmaca H, Colak R. Visual field defects in 23 acromegalic patients. Int Ophthalmol. 2013 Oct;33(5):521-5.Crossref PubMed

4.Ogra S, Nichols AD, Stylli S, Kaye AN, Savino PJ, Danesh-Meyrr HV. Visual acuity and pattern of visual field loss at presentation in pituitary adenoma. J Clin Neurosci. 2014; 21(5):735-40.Crossref PubMed

5.Kim SH, Lee KC, Kim SH. Cranial nerve palsies accompanying pituitary tumour. J of Clinical Neurosci. 2007 Dec;14(12): 1158-62.Crossref PubMed

6.Chuang CC, Chen E, Huang YC, Tu PH, Chen YL, Pai PC. Surgical outcome of oculomotor nerve palsy in pituitary adenoma. J Clin Neurosci. 2011 Nov;18(11):1463-8.Crossref PubMed

7.Hage R, Eshraghi SR, Oyesiku NM, Ioachimescu AG, Newman NJ, Biousse V, et al. Third, fourth, and sixth cranial nerve palsies in pituitary apoplexy. World Neurosurg. 2016 Oct;94:447-452.Crossref PubMed

8.Nishimura M, Kurimoto T, Yamagata Y, Ikemoto H, Arita N, Mimura O. Giant pituitary adenoma manifesting as homonymous hemianopia. Jpn J Ophthalmol. 2007 Mar-Apr;51(2):151-3.Crossref PubMed

9.Kitthaweesin K, Ployprasith C. Ocular manifestations of suprasellar tumors. J Med Assoc Thai. 2008; 91(5):711-5.

10.World Health Organization. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 2005; 41(10):1403-9.Crossref 

11.Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with a pituitary adenoma. Pituitary. 2003 Sep;6(2):81-7.Crossref PubMed

12.Aaronson NK. Quality of life: what is it? How should it be measured? Oncology (Williston Park). 1988 May;2(5):69-76, 64.

13.Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-Item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001; 119(7):1050-8.Crossref PubMed

14.Wolf A, Goncalves S, Salehi F, Bird J, Cooper P, Van Uum S, et al. Quantitative evaluation of headache severity before and after endoscopic transsphenoidal surgery for pituitary adenoma. J Neurosurg. 2017; 127(2):409-16.Crossref PubMed

15.Makarenko OV, Kryvoviaz OV, Kryvoviaz SO. [Assessment of the quality of life in patients with primary open-angle glaucoma and approaches to rational pharmacotherapy in this pathology]. Ratsionalna farmakoterapiia. 2016; 2(39): 32-40. Ukrainian.

16.Muslimova ZR. [Rehabilitation treatment of patients with ocular disturbances after removal of tumors of the chiasm and sellar region]. Thesis for the degree of Cand Sc (Med). St Petersburg; 2017. Russian.


The authors certify that they have no conflicts of interest in the subject matter or materials discussed in this manuscript.